By Mill Chart
Last update: Dec 12, 2023
Uncover the hidden value in GILEAD SCIENCES INC (NASDAQ:GILD) as our stock screening tool recommends it as an undervalued choice. NASDAQ:GILD maintains a robust financial position and offers an attractive pricing perspective. Let's dig deeper into the analysis.
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NASDAQ:GILD has earned a 7 for valuation:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:GILD has achieved a 8:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:GILD, the assigned 5 for health provides valuable insights:
Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:GILD boasts a 4 out of 10:
More Decent Value stocks can be found in our Decent Value screener.
Check the latest full fundamental report of GILD for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
GILEAD SCIENCES INC
NASDAQ:GILD (4/26/2024, 7:00:00 PM)
After market: 65.5 +0.08 (+0.12%)65.42
+0.15 (+0.23%)
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.
GILD earnings call for the period ending March 31, 2024.
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gilead Sciences (NASDAQ:GILD) just reported results for the first quarter of 20...
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top S&P500 gainers and losers in today's after hours session.
Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury.
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).